Update on statin-associated myopathy symptoms in the view of new clinical management strategies
- 12 June 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 38 (5) , 551-559
Abstract
Purpose of review: Purpose of this review is to highlight the recent findings in terms of clinical aspects, pathogenic mechanisms and managements of statin associated muscle symptoms (SAMS), and focusing on the use of novel therapeutic alternatives in clinical practice. Recent findings: While extensive research has been conducted on SAMS, the precise mechanisms remain unclear. Recent findings continue to explore various aspects, including potential risk factors, diagnostic approaches, and management strategies. Managing SAMS involves a careful assessment to confirm the diagnosis, a stepwise approach to treatment that may include dose adjustments, switching statins, considering alternate-day dosing, and exploring nonstatin therapies, all while prioritizing patient well being and cardiovascular risk reduction through shared decision-making and ongoing monitoring. In recent years, the therapeutic landscape has expanded with the introduction of several novel lipid-lowering agents, providing valuable alternatives for both statin-tolerant and statin-intolerant patients but their use in clinical practice is still limited because of high costs, regulatory limitations and type of administration. Summary: Given the increasing use of both traditional and emerging lipid-lowering therapies, a clear understanding of their comparative safety, particularly regarding musculoskeletal adverse effects, is essential for guiding clinical decision-making.Keywords
This publication has 54 references indexed in Scilit:
- 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)Drugs, 2024
- Skeletal muscle fibre type-dependent effects of atorvastatin on the PI3K/Akt/mTOR signalling pathway and atrophy-related genes in ratsMolecular Biology Reports, 2024
- Decoding the Intricacies of Statin-Associated Muscle SymptomsCurrent Rheumatology Reports, 2024
- The Role of Mitochondria in Statin-Induced MyopathyDrug Safety, 2024
- Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophyThe American Journal of Human Genetics, 2023
- Statin intolerance management: a systematic reviewEndocrine, 2022
- Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)Journal of Cachexia, Sarcopenia and Muscle, 2022
- Statin Induced Myopathy Among Patients Attending the National Center for Diabetes, endocrinology, & geneticsAnnals of Medicine & Surgery, 2022
- Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissueCell Biology and Toxicology, 2020
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016